Physician profile
Anthony Quartell
NPI 1154424786
$2,895.02
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $727 · 2021: $374 · 2022: $103 · 2023: $107 · 2024: $51.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $1,500.00 | 2019-2020 | |
| Therapeuticsmd, INC. | $303.93 | 2019-2022 | |
| Abbvie INC. | $162.20 | 2019-2022 | |
| Stryker Corporation | $135.59 | 2021 | |
| Avion Pharmaceuticals | $94.89 | 2019-2021 | |
| Ethicon INC. | $90.09 | 2019 | |
| Applied Medical Resources Corporation | $78.82 | 2021 | |
| Mayne Pharma Commercial LLC | $60.52 | 2022-2023 | |
| Pfizer INC. | $52.78 | 2020-2024 | |
| Vertical Pharmaceuticals, LLC | $44.98 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.85 | 2019-2023 | |
| Roche Diagnostics Corporation | $40.86 | 2019-2021 | |
| Myovant Sciences INC. | $38.57 | 2021-2022 | |
| Allergan, INC. | $37.13 | 2019 | |
| Exeltis, USA INC. | $36.92 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $27.82 | 2019-2021 | |
| Astellas Pharma US INC | $20.87 | 2024 | Veozah |
| Olympus America INC. | $19.55 | 2023 | Endoeye Flex 3d Deflectable Videoscope |
| Sumitomo Pharma America, INC. | $17.00 | 2024 | Myfembree |
| Coopersurgical, INC. | $17.00 | 2023 | Paragard T 380a |
| Mycovia Pharmaceuticals, INC. | $14.69 | 2023 | Vivjoa |
| Organon LLC | $14.33 | 2023 | Nexplanon |
| Dysis Medical, INC. | $14.31 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.23 | 2019 | |
| Millicent US INC | $14.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Quartell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.